Shares drop as company forecasts lower earnings and sales

  • Repligen stock falls 10% after soft 2024 guidance
  • Shares down to $180 in premarket trading
  • 2024 adjusted earnings forecast below analyst expectations
  • Revenue target also falls short of estimates
  • Challenges in China cited as reason for soft guidance

Shares of Repligen fell 10% to $180 in premarket trading after the life-sciences company issued soft earnings and sales guidance for 2024. The company’s adjusted earnings forecast of $1.42 to $1.49 a share fell below analyst expectations of $1.77 a share. Similarly, Repligen’s revenue target of $620 million to $650 million fell short of the $660.7 million that analysts had expected. The company cited challenges in China as the reason for the soft guidance. Despite this, Chief Executive Tony Hunt expressed optimism that the markets would improve as they advanced through 2024, with growth accelerating in the second half of the year.

Factuality Level: 8
Factuality Justification: The article provides factual information about Repligen’s soft earnings and sales guidance for the year, including specific numbers and quotes from the company’s CEO. There are no obvious signs of bias, sensationalism, or inaccuracies in the reporting.
Noise Level: 3
Noise Justification: The article provides relevant information about Repligen’s soft earnings and sales guidance, the reasons behind it, and the CEO’s statement. However, it lacks in-depth analysis, antifragility considerations, and accountability of powerful people. The article stays on topic and supports its claims with data, but it could benefit from more actionable insights or solutions for investors.
Financial Relevance: Yes
Financial Markets Impacted: Repligen
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses Repligen’s soft earnings and sales guidance for the year. There is no mention of an extreme event.
Public Companies: Repligen (unknown)
Key People: Tony Hunt (Chief Executive)

Reported publicly: www.marketwatch.com